Disease: Metastatic Clear Renal Cell Carcinoma, RCC, (ALLO-316)

Disease info:

Renal cell cancer (also called kidney cancer or renal cell adenocarcinoma) is a disease in which malignant (cancer) cells are found in the lining of tubules (very small tubes) in the kidney. There are 2 kidneys, one on each side of the backbone, above the waist. Tiny tubules in the kidneys filter and clean the blood. 

Cancer that starts in the ureters or the renal pelvis (the part of the kidney that collects urine and drains it to the ureters) is different from renal cell cancer. 

The prognosis and treatment options depend on the stage of the disease, and the patient's age and general health. After renal cell cancer has been diagnosed, tests are done to find out if cancer cells have spread within the kidney or to other parts of the body. The cancer may come back in the kidney or in other parts of the body after initial treatment.

There are different types of treatment for patients with renal cell cancer. Five types of standard treatment are used:

  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted therapy

New types of treatment are being tested in clinical trials. Patients can enter clinical trials before, during, or after starting their cancer treatment. Follow-up tests may be needed.

Frequency:
Renal cell carcinoma (RCC), affects more than 30,000 people annually and 40% of them die due to complications from this cancer. Kidney cancer is the ninth and fourteenth common cancer cases in men and women, respectively worldwide according to 2018 data.
Official title:
ALLO-316
Who:
Partners:

No 

Locations:
Study start:
Enrollment:
Gene editing method:
TALENs
Type of edit:
Gene knock-out, gene knock-in
Gene:
CD52 molecule, T Cell Receptor Alpha Constant (TRAC), anti-CD70 CAR,
Delivery method:
Lentivirus (LV) and Electroporation - Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status:

Description

AlloCAR T therapy uses T cells from healthy donors. These cells are isolated in a manufacturing facility, engineered to express CARs to recognize and destroy cancer cells, and modified via gene editing to limit autoimmune response when given to a patient.

The process for manufacturing Allogenes' investigational off-the-shelf AlloCAR T therapy begins by harvesting healthy, selected, screened and tested T cells from healthy donors.Next, the T cells are engineered to express CARs, which recognize certain cell-surface proteins that are expressed in hematologic or solid tumors (i.e CD70 molecule).The next step in the process involves gene editing to reduce the risk of graft-vs-host disease (GVHD) and allogeneic rejection. A T cell receptor gene is knocked out to avoid GVHD. The CD52 gene is knocked out to render the CAR T product resistant to anti-CD52 antibody treatment. The engineered T cells then undergo a purification step and are ultimately cryopreserved in vials for delivery to patients.

Last updated: Dec. 23, 2020
Source: US National Institutes of Health (NIH)
clinicaltrials.gov
close
Search CRISPR Medicine